Athelas Ltd., (Geneva, Switzerland) is a drug discovery company developing a novel class of drugs to treat bacterial infectious diseases. Contrary to conventional antibiotics, Athelas' drugs treat bacterial infections by targeting mechanisms that are essential for bacterial colonization, invasion and  survival only when bacteria are within the host' environment.

Athelas was acquired by MerLion Pharmaceuticals as of August 21, 2006.